Literature DB >> 2555339

Platelet receptor occupancy with factor IXa promotes factor X activation.

S S Ahmad1, R Rawala-Sheikh, P N Walsh.   

Abstract

To investigate the activated platelet surface as a locus for factor X activation, the functional consequences of factor IXa binding to platelets were studied. The concentration of factor IXa required for half-maximal rates of factor X activation in the presence of factor VIIIa and thrombin-activated platelets was 0.53 nM, which is close to the Kd (0.56 nM) for factor IXa binding to platelets under identical conditions, determined from equilibrium binding studies. In direct comparative experiments, there was a close correspondence between equilibrium binding of factor IXa to thrombin-activated platelets in the presence of factor VIIIa and kinetic determinations of factor X activation rates. Analysis by polyacrylamide gel electrophoresis revealed that 125I-labeled factor IXa bound to platelets was structurally intact and did not form covalent complexes with platelet proteins. Factor IXa active site-inhibited by 5-dimethylaminonaphthalene-1-sulfonyl glutamyl-glycylarginyl chloromethyl ketone was shown to be a competitive inhibitor of factor IXa binding in the absence (Ki = 2.3 nM) and presence (Ki = 0.43 nM) of factor VIIIa and factor X and of factor X activation (Ki = 0.4 nM) by factor IXa in the presence of factor VIIIa, indicating that the generation of factor Xa is not required for factor IXa binding and that factor IXa bound to activated platelets in the presence of factor VIIIa is closely coupled with rates of factor X activation. We conclude that factor IXa bound tightly to a platelet receptor in the presence of factor VIIIa is the enzyme active in factor X activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555339

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium.

Authors:  Fredda S London; Mariola Marcinkiewicz; Peter N Walsh
Journal:  Biochemistry       Date:  2006-06-13       Impact factor: 3.162

2.  Measurement of procoagulant platelet subpopulations in whole blood: development of an assay for population-based studies.

Authors:  Beth A Bouchard; Aimee K Paradis; Kathleen E Brummel-Ziedins
Journal:  Thromb Res       Date:  2010-06-11       Impact factor: 3.944

3.  Protease nexin-2/amyloid beta-protein precursor: a cerebral anticoagulant?

Authors:  D D Cunningham
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex.

Authors:  Xia Yang; Peter N Walsh
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  New developments in anticoagulation for atrial fibrillation.

Authors:  M Haris U Usman; Lawrence A Notaro; Harsh Patel; Michael D Ezekowitz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

6.  Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa.

Authors:  Mikhail A Panteleev; Evgueni L Saenko; Natalya M Ananyeva; Fazoil I Ataullakhanov
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

Review 7.  Advancement in antithrombotics for stroke prevention in atrial fibrillation.

Authors:  Mohammed Haris Umer Usman; Sabreen Raza; Shariq Raza; Michael Ezekowitz
Journal:  J Interv Card Electrophysiol       Date:  2008-04-17       Impact factor: 1.900

8.  ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor.

Authors:  Anthony N Vomund; Elaine M Majerus
Journal:  J Biol Chem       Date:  2009-09-03       Impact factor: 5.157

9.  Functional assembly of intrinsic coagulation proteases on monocytes and platelets. Comparison between cofactor activities induced by thrombin and factor Xa.

Authors:  M P McGee; L C Li; M Hensler
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.